A drug licensed from Pfizer will be submitted to FDA next year in dermatomyositis after study results showed it reduced ...

One of the biggest advantages of the new polymer-based nanoparticles over current lipid-based models is the potential for low ...

Data derived from Daneshmand S, et al. J Clin Oncol. 2025;doi:10.1200/JCO-25-01651.A novel drug-releasing system for bladder cancer that allows for sustained delivery of medicine for several weeks ...

Discover investment opportunities in Rezolute, Inc. as new drug ersodetug advances in phase 3 HI trials, with catalysts ...